OLMA — OLEMA PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About OLEMA PHARMACEUTICALS INC (OLMA)
OLEMA PHARMACEUTICALS INC (OLMA) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $34M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in OLMA
How many top investors track OLMA
A small number of top investors own this.
OLMA Ownership Composition
How OLEMA PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Other95.4%
- Hedge Funds4.6%
Tracked investors reporting OLMA
- Ken GriffinMar 31, 2026Citadel AdvisorsShares1.1MValue$16.5M% Portfolio0.00%
- Stanley DruckenmillerMar 31, 2026Duquesne Family OfficeShares986.8KValue$14.7M% Portfolio0.44%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares182.9KValue$2.7M% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares109.7KValue$1.6M% Portfolio0.00%
Recent activity
- New$16.5MMay 15, 2026
- $14.7MMay 15, 2026
Frequently asked questions
- How many institutional investors hold OLMA?
- 4 tracked institutional investors disclosed a position in OLMA (OLEMA PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of OLMA?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in OLMA, valued at $34M.
- Did institutional ownership of OLMA increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 0 fully exited OLMA.
- Where does this OLMA ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.